icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Boston MA
November 2019
Back grey_arrow_rt.gif
Drug Use and Reinfection Following HCV Treatment With Elbasvir/Grazoprevir Among Patients Receiving Opioid Agonist Therapy: Final Results From the CO-STAR Study
  AASLD 2019 Nov 8-11 Boston
Reported by Jules Levin
Jason Grebely1; Brian Conway2; Alain H. Litwin3; Olav Dalgard4; Oren Shibolet5; Ronald Nahass6; Frederick Altice7; Edward J. Gane8; Anne Luetkemeyer9; Cheng-Yuan Peng10; David Iser11; Isaias Noel Gendrano12; Michelle M. Kelly12; Peggy Hwang12; Ernest Asante-Appiah12; Eliav Barr12; Michael N. Robertson12; Heather Platt12; Gregory J. Dore1 1The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; 2Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 3Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA; 4Institute of Clinical Medicine, Akershus University, Oslo, Norway; 5Liver Unit, Department of Gastroenterology, Tel Aviv Medical Center and Tel Aviv University, Tel Aviv, Israel; 6ID Care, Hillsborough, NJ, USA; 7Yale University, New Haven, CT, USA; 8Auckland City Hospital, Auckland, New Zealand; 9University of California, San Francisco, San Francisco, CA, USA; 10China Medical University Hospital, Taichung, Taiwan; 11The Alfred Hospital, Melbourne, VIC, Australia; 12Merck & Co., Inc., Kenilworth, NJ, USA